Journal Publications

Expand All

2018

2017


Journal Publications
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


2016


• Chapman JA, Sgroi DC, Goss PE, Zarela E, Binns S, Zhang Y, Schnabel CA, Erlander


- Jiang S, Chen B, Tu D. Inference on treatment-covariate interaction based on a nonparametric measure of treatment effects and censored survival data. Statist Med n/a, 2016.


2015


• Brulé SY, Jonker DJ, Karapetis CS, O’Callaghan CJ, Moore MJ, Wong R, Tebbutt NC,


- Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, Chirieac L,


2014


- Robinson AG, Booth CM, Eisenhauer EA. Progression-free survival as an end-point in solid tumours - Perspectives from clinical trials and clinical practice. Eur J Can 50: 2303-8, 2014.


• Hilton JF, Tu D, Seymour L, Shepherd FA, Bradbury PA. An evaluation of the possible interaction of gastric acid suppressing medication and the EGFR tyrosine kinase inhibitor erlotinib. Lung Cancer 2013.


randomized trial of dasatinib 100 mg vs imatinib 400 mg in newly diagnosed chronic phase chronic myeloid leukemia. Blood 120: 3898-905, 2012.


- White DJ, Bahlis NJ, Marcellus DC, Belch A, Stewart AK, Chen C, Kovacs MJ,


2012

- Cheang MC, Voduc KD, Tu D, Jiang S, Leung S, Chia SK, Shepherd L, Levine MN,


Gospodarowicz MK, Mason M, Parulekar W, Swanson G, Kirkbride P, Brundage M,

- Jiang S, Tu D. Inference on the probability as a measurement of treatment effect under a density ratio model and random censoring. Computational Statistics and Data Analysis 56: 1069-78, 2012.
- Macdonald DA, Assouline SE, Brandwein J, Kamel-Reid S, Eisenhauer EA, Couban S, Caplan S, Foo A, Walsh W, Leber B. A Phase I/ll Study of Sorafenib (BAY 43-9006) In Combination with Low Dose Cytarabine (LDAC) In Elderly Patients with AML or High-
Risk MDS from the NCIC Clinical Trials Group: Trial IND.186 (ONLINE). Leuk Lymphoma 2012.


2011

- Brundage M, Bass B, Davidson J, Queenan J, Bejak J, Ringash J, Wilkinson A, Feldman-Stewart D. Patterns of reporting health-related quality of life outcomes in


- Goodwin PJ, Stambolic V, Lemieux J, Chen BE, Parulekar WR, Gelmon KA, Hershman


• Lyerly HK, Abernethy AP, Stockler MR, Koczwara B, Aziz Z, Nair R, Seymour L. Need for Global Partnership in Cancer Care: Perceptions of Cancer Care Researchers Attending the 2010 Australia and Asia Pacific Clinical Oncology Research Development


- O'Malley FP, Chia S, Tu D, Shepherd LE, Levine MN, Huntsman D, Bramwell VH, Andrilis IL, Pritchard KL. Topoisomerase II alpha protein and responsiveness of breast cancer to adjuvant chemotherapy with CEF compared to CMF in the NCIC CTG randomized MA.5 adjuvant trial. Breast Cancer Res Treat 128: 401-9, 2011.


- Sargent D, Shi Q, Yothers G, Van CE, Cassidy J, Saltz L, Wolmark N, Bot B, Grothey A, Buyse M, de GA. Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803. Eur J Cancer 47: 990-6, 2011.


2010

- da Cunha Santos G, Dhani N, Tu D, Chin K, Ludkovski O, Kamel-Reid S, Squire J,


Mackay HJ, Gallinger S, Tsao MS, McLachlin CM, Tu D, Keiser K, Eisenhauer EA, Oza AM. Prognostic value of microsatellite instability (MSI) and PTEN expression in women with endometrial cancer: Results from studies of the NCIC Clinical Trials Group (NCIC CTG). Eur J Can 46: 1365-73, 2010.


Pisters KMW, Vallières E, Crowley JJ, Franklin WA, Bunn PA, Ginsberg RJ, Putnam JB, Chansky K, Gandara D. Surgery With or Without Preoperative Paclitaxel and Carboplatin in Early-Stage Non-Small-Cell Lung Cancer: Southwest Oncology Group


2009


2008


- Hicks LK, Haynes AE, Reece DE, Walker IR, Herst JA, Meyer RM, Imrie K, Hematology Disease Site Group of the Cancer Care Ontario Program in Evidence-based Care. A meta-analysis and systematic review of thalidomide for patients with previously


2007


Siu L, Soulieres D, Chen EX, Pond GR, Chin SF, Francis P, Harvey L, Klein M, Zhang


2006


- Tong FK, Chow S, Hedley D. Pharmacodynamic monitoring of BAY 43-9006 (Sorafenib) in phase I clinical trials involving solid tumor and AML/MDS patients, using flow cytometry to monitor activation of the ERK pathway in peripheral blood cells. Cytometry B Clin Cytom 70: 107-14, 2006.


2005


- Byrd JC, Rai K, Peterson BL, Appelbaum FR, Morrison VA, Kolitz JE, Shepherd L, Hines JD, Schiffer CA, Larson RA. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB


- Ouyang Y, Li D, Pater JL, Levine M. The importance of temporal effects in evaluating


2004


- Parulekar WR, Eisenhauer EA. Phase I trial design for solid tumour studies of targeted,


- Crump M, Tu D, Shepherd L, Levine M, Bramwell V, Pritchard K. Risk of acute leukemia following epirubicin-based adjuvant chemotherapy: a report from the NCIC Clinical Trials
Journal Publications
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


Cripps MC, Figueredo AT, Oza AM, Taylor MJ, Fields AL, Holmlund JT, MacIntosh LW, Geary RS, Eisenhauer EA. Phase II randomized study of ISIS 3521 and ISIS 5132 in...


2001


2000


Gelmon KA, Latreille J, Tolcher A, Genier L, Fisher B, Forand D, D'Aloisio S, Vernillet L, Daigneault L, Lebecq A, Besenval M, Eisenhauer E. Phase I dose-finding study of a new taxane, RPR 109881A, administered as a one-hour intravenous infusion days 1 and 8 to


1999


- Osoba D. What has been learned from measuring health-related quality of life in clinical oncology. Eur J Can 35: 1565-70, 1999.


1998

• Levine M, Pritchard K, Bramwell V, Shepherd L. Adjuvant chemotherapy with CEF


• Siu LL, Oza AM, Eisenhauer EA, Firby PS, Thiessen JJ, Michael M, Wainman N, Manzo J, Feld R, Goldberg RA, Moore MJ. Phase I and pharmacological study of


1997


- Osoba D, Aaronsen N, Zee B, teVelde A, Sprangers M. Modification of the EORTC QLQ-C30 (version 2.0) based on content validity and reliability testing in large samples of patients with cancer. Quality of Life Research 6: 103-8, 1997.
- Tu D. A comparative study of some statistical procedures in establishing therapeutic


1996

- Dent S, Eisenhauer E. Phase I trial design: are new methodologies being put into practice? Ann Oncol 7: 561-6, 1996.
- Osoba D, Dancey J, Zee B, Myles J, Pater J. Health-related quality-of-life studies of the


1995


• Payne D, Coy P, Hodson I, Murray N, Pater J, Wilson K. Coy et al. original article (Patterns of failure following loco-regional radiotherapy in the treatment of limited stage...


1994


1993

301-8, 1993.


1991


1990


1989


1988


Journal Publications
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


1987

- Quirt I, Eisenhauer E, Bramwell V, Knowling M, Grafton C, Hirte W, Cripps M, Maksymiuk A. Phase II study of mitroxastrone in untreated and previously minimally


1986

1985


1984

- Pater J, Willan A. Clinical trials as diagnostic tests. Controlled Clin Trials 5: 107-13,
1984.

1980


1979